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Abstract: Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent
kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast
cancer. Interindividual variability in the therapeutic response of CDKis has been reported and
some individuals may experience increased and unexpected toxicity. This narrative review aims
at identifying the factors potentially concurring at this variability for driving the most appropriate
and tailored use of CDKis in the clinic. Specifically, concomitant medications, pharmacogenetic
profile, and pathophysiological conditions could influence absorption, distribution, metabolism,
and elimination pharmacokinetics. A personalized therapeutic approach taking into consideration all
factors potentially contributing to an altered pharmacokinetic/pharmacodynamic profile could better
drive safe and effective clinical use.
Keywords: cyclin-dependent kinases inhibitors; breast cancer; personalized medicine
1. Introduction
The complexes composed by cyclins and cyclin-dependent kinases (CDKs) are critical checkpoints
in the progression of the cell cycle and some mutations on this pathway have been demonstrated
to be involved in cancer [1]. In breast cancer, CDK4 and CDK6 inhibitors (CDKis) have emerged as
key players in the cellular proliferation through different pathways [2,3]. The mechanism of action of
CDKis is shown in Figure 1.
Breast cancer represents an interesting pathological setting where CDKis constitute a current
therapeutic tool and also provide the most advanced perspectives, especially in advanced hormone
receptor (HR)-positive (estrogen receptor-positive and/or progesterone receptor-positive) and human
epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer [2,4,5].
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Figure 1. In red the enzymatic reactions prevented by CDK inhibitors are shown. Physiologically,
growth signals induce the expression of Cyclin D which binds CDK4 or CDK6; this CDK-Cyclin complex
promotes the hyper-phosphorylation of the tumor suppressor protein RB1 which is bound to the E2F
transcription factor, determining its release and the consequent expression of genes implicated in cellular
entry in S phase and proliferation, as topoisomerase-IIα. The hyper-expression of Cyclin D is shown in
hyper-activated cellular signaling, involved in the oncogenesis of several tumors, as RAS/RAF/MEK/ERK
and PI3K/AKT/mTOR pathways. When CDK inhibitors are used, the hyper-phosphorylation of the
RB1 by complex CDK-Cyclin D and the consequent transcription of important enzymes allowing the
transition from G1 to S phase of cell-cycle, such as topoisomerase-Iiα, are prevented. CDK—Cyclin
Dependent Kinase; RB1—RB transcriptional corepressor 1; P—Phosphate group.
The EMA and FDA have approved palbociclib, ribociclib, and abemaciclib in combination therapy
with aromatase inhibitors (anastrozole/letrozole) or fulvestrant. In this clinical setting, CDKis used as
first-line therapy showed an improvement of progression-free survival (PFS) from 14–16 months in the
placebo arms to ≥25 months in the experimental arm with palbociclib, ribociclib or abemaciclib
as demonstrated in their registration trials: PALOMA-2, MONALEESA-2, and MONARCH-3
respectively [6–8]. In the MONALEESA-7 trial ribociclib showed similar efficacy in combination with
ovarian suppressor and tamoxifen or aromatase inhibitor at the same setting in premenopausal
women [9]. Nevertheless, regulatory agencies do not approve the combination ribociclib and
tamoxifen, due to safety reasons related to increased QT prolongation [10,11]. When CDKis are
used in second-line therapy, due to relapse on aromatase inhibitors, they doubled PFS in combination
with fulvestrant compared to fulvestrant alone, as demonstrated in PALOMA-3, MONALEESA-3,
and MONARCH-2 [12–14].
FDA approved abemaciclib also as monotherapy for the treatment of adult patients with
HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following
endocrine therapy and prior chemotherapy in the metastatic setting. On the contrary, EMA did not
approve abemaciclib in monotherapy considering that MONARCH-1 is a phase II single-arm open-label
study, characterized by heterogeneous study population, due to wide inclusion criteria (women who
had progressed on or after prior endocrine therapy and had one or two chemotherapy regimens) [15,16].
Furthermore, the post-marketing observational data from the Flatiron Health database were used as
historic cohort to compare MONARCH-1 data, but different endpoints between the two studies make
them not directly comparable and no robust clinical evidence was assessed by EMA to support the
approval of abemaciclib as monotherapy [16].
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Palbociclib, ribociclib and abemaciclib share the same mechanism of action and show similar
pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Nonetheless, some discrepancies in
their PK and CDKs isoforms selectivity need to be outlined. It can account for different response to
treatment highlighted in some studies [17]. Differently from registration trials, in clinical practice all
factors that may interfere with PK/PD and toxicological properties of investigated drugs and related
to concomitant epidemiological, genetic and clinical conditions should be taken in consideration
by clinicians. In this regard, a meta-analysis of clinical trials involving CDKis in combination with
aromatase inhibitors or tamoxifen suggests a higher absolute prevalence of some adverse events in a
subgroup composed by asiatic patients compared with the non-Asian group. A significantly different
efficacy profile was also found in the same patients’ subgroup [18,19]. This phenomenon has been
proposed to be ascribable not only to the different epidemiology features of breast cancer in Asiatic
patients, but also to specific multifactorial causes. In particular, they concern: a) differences in body
size, which can result a critical issue due to the fixed-dose schedule of these drugs [20,21]; b) diet, where
relevant intake of soy influences drugs metabolism [22]; c) a different expression of proinflammatory
genes involving the oncogenesis; d) genetic background of enzymes involved in CDKis absorption,
distribution, metabolism, and elimination (ADME), as suggested by higher average Cmax and AUC
values of ribociclib in Japanese patients [19,23,24]. In our opinion, this latter point suggests a key-role
of both cytochromes and transporters in influencing the ADME of CDKis PK and consequently their
own tolerability profiles.
The aim of this review is to discuss possible meaningful clinical interactions between CDKis and
co-administered drugs (drug-drug interactions, DDIs), pharmacogenetics (drug-gene interactions,
DGIs) and pathophysiological conditions that may occur at all levels of ADME. The differences in
CDKis pharmacological features could be further exacerbated by decreasing or increasing their oral
bioavailability, distribution, and/or toxicity. With regard to all these aspects, not considered in CDKis
phase III-IV trials, we aim to focus on patient’s features (DDIs, DGIs, and pathophysiological conditions)
to foster a more personalized use of these agents [25].
1.1. Pharmacodynamics
Palbociclib, ribociclib and abemaciclib selectively and reversibly inhibit CDK4/6 binding to ATP
pocket of the inactive complex by two hydrogen bonds. In enzymatic assays, each compound shows a
different potency in the activity against CDK4 or CDK6. Palbociclib shows a similar activity for CDK4
and CDK6 (CDK4 IC50 = 11 nmol/L vs. CDK6 IC50 = 16 nmol/L), while ribociclib potency is higher for
CDK4 than for CDK6 (CDK4 IC50 = 10 nmol/L vs. CDK6 IC50 = 39 nmol/L) [26]. Abemaciclib is the most
potent inhibitor, especially toward CDK4 (CDK4 IC50 = 2 nmol/L vs. CDK6 IC50 = 10 nmol/L) [26–29].
Abemaciclib, by virtue of its functional group, achieves a better steric complementarity in the CDK4/6
ATP cleft compared to palbociclib and ribociclib [30]. Besides presenting a higher potency toward
CDK4 inhibition, abemaciclib, when higher concentration is achieved, shows the least selectivity
against CKDs-cyclins complex compared to palbociclib and ribociclib, as additional interactions occur
with other redundant CDK isoforms (Table 1) [31–33]. Hence, abemaciclib conducts its main efficacy
effect targeting CDK4, and secondly, with a lower potency, CDK9 and to an even lesser extent CDK6,
responsible for suppressing RB1 phosphorylation and the cell cycle arrest in the G1 phase overall [2,16].
Interestingly, abemaciclib, independently from CDKs pathways, presents multiple mechanisms
of action compared to palbociclib and ribociclib, inhibiting other kinases that are involved in many
processes influencing cellular proliferation, inflammation, and oncogenesis (Table 1).
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Table 1. Molecular pathways of kinases which are targeted by palbociclib, ribociclib and abemaciclib.
The grading of affinity between CDKis and each target kinase is arbitrary expressed by -, no affinity; +,
presence of affinity; ++, high affinity; +++, very high affinity.
Targeted Kinase Pathophysiological Activities of Targeted Kinases Affinity ofPalbociclib
Affinity of
Ribociclib
Affinity of
Abemaciclib
CDK1 It is mainly involved in controlling the transition from G2 to Mphase of cell-cycle - - +
CDK2 It selectively orchestrates processes of phase S, binding CyclinE, and not Cyclin D as for the other CDKs - - +
CDK4
It inhibits members of the retinoblastoma (RB) protein family
including RB1 and regulate the cell-cycle during G(1)/S
transition [34]
++ +++ +++
CDK6
It inhibits members of the retinoblastoma (RB) protein family
including RB1 and regulate the cell-cycle during G(1)/S
transition [34]
++ ++ +
CDK7
It regulates the initiation of transcription through
phosphorylation of the heptad repeats that comprise the
C-terminal tail of RNA polymerase II (CTD)
- - +
CDK9
It regulates the release from promoter proximal arrest of
transcription through phosphorylation of the heptad repeats
that comprise the C-terminal tail of RNA polymerase II (CTD)
- - ++
GSK3 α/β It promotes the synthesis of pro-inflammatory IL-6 and theexpression of oncogenic genes - - +
CAMKII α/β/γ It is involved in apoptosis and autophagy in cancer cells - - +
DYRK It regulates some proteins controlling the cell cycle - - +
PIM protein kinase It is an oncogenic protein which is frequently amplifiedin cancer - - +
HIPK It promotes JAK/STAT signaling - - +
CAMK families They are enzymes overexpressed in several cancer types - - +
CDK—Cyclin Dependent Kinase; GSK3 α/β—glycogen synthase kinase 3α/β; CAMKII
α/β/γ—calmodulin-dependent protein kinase II α/β/γ; DYRK—dual-specificity tyrosine phosphorylation-regulated
kinase; HIPK—homeodomain-interacting protein kinase; CAMK—Ca2+/calmodulin-stimulated protein kinase;
JAK—Janus Kinase; STAT—Signal Transducer and Activator of Transcription.
1.2. Safety
By virtue of CDKis PD properties and CDK activity in cell-cycle, palbociclib, ribociclib and
abemaciclib share a common toxicity profile against high proliferative tissue (e.g., bone marrow and
gastrointestinal mucosa), consisting in hematological and gastrointestinal disorders such as anemia,
neutropenia, white blood cells decrease, nausea, vomiting and diarrhea [11,16,35]. Nevertheless,
palbociclib, ribociclib and abemaciclib show a better efficacy and safety profile compared with the first
and the second generations of CDK inhibitors, which instead target all or most of CDK isoforms [36].
This promiscuity toward CDK isoforms often resulted in a jeopardizing inability to discriminate
physiological and malignant proliferative processes, inducing severe cytotoxicity (myelosuppression
and anemia) [36]. Through an increased selectivity, new CDKis show less common and severe
hematological adverse events [31]. Gastrointestinal disorders are instead the most frequent adverse
events recorded for abemaciclib with higher incidence of nausea and severe diarrhea compared with
palbociclib and ribociclib. For these reasons abemaciclib should not be recommended in patients
with gastrointestinal comorbidities [16,37,38]. The different abemaciclib tolerability profile could be
attributed to the main involvement of CDK9, compared to CDK6 which is remarkably implicated in
hematopoiesis [37]. Consequently, myelosuppression and anemia are less frequent, and neutropenia is
quite easily manageable, compared to palbociclib and ribociclib. Furthermore, the safer abemaciclib
profile compared with first and second generation CDK inhibitors could be ascribed to its lower
potency against CDK1, CDK7, and CDK9, overall [31]. Interestingly, abemaciclib-induced diarrhea can
significantly reduce its absorption, so that a prophylactic dose of loperamide 8 mg could be usually
recommended [3].
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A very relevant safety issue concerns ribociclib and arrhythmias. In fact, ribociclib in phase III trials
has been associated to QT interval prolongation, distinguishing from palbociclib and abemaciclib [11].
A recent pooled safety analysis (1065 patients treated with ribociclib vs. 818 patients with placebo)
shows that the QT interval corrected for heart rate (QT-c) and calculated by the Fridericia formula
(QTcF) >480 ms occurred in 5% vs. 1% of patients in the ribociclib vs. placebo arms, whereas a QTcF
>500 ms occurred in 1% vs. <1% of patients respectively [39]. On the contrary, no relevant adverse event
related to prolonged QT is reported for palbociclib and abemaciclib [40,41]. For this reason, ribociclib
should be avoided in case of patients suffering from relevant cardiological disease (bradyarrhythmia,
long QT syndrome, recent ischemic myocardial syndrome, heart failure and electrolyte abnormalities)
or assuming concomitant medications directly or indirectly inducing QT prolongation. For patients
starting with ribociclib, an electrocardiography (ECG) monitoring is required in order to observe
electrophysiological consequences [11]. Palbociclib and abemaciclib, differently from ribociclib, have
no direct QT interval influence, nevertheless the co-administration of drugs that prolong QT is
discouraged [16,35].
A summary of main safety issues recorded in registration trials of each compound is reported in
Table 2. Post-registration safety data warn against the increased risk of venous thromboembolism (VTE)
and pulmonary embolism in patients treated with abemaciclib, as reported in abemaciclib leaflet [16].
Nevertheless, increasing evidences stress on the higher risk of VTE for all the aforementioned CDKis
than the placebo group, suggesting caution and additional monitoring of patients on treatment with
CDKis [42]. For a possible rationale for CDKis selection according to pathophysiological conditions,
see Section 7.
1.3. Pharmacokinetics
Oral agents are usually characterized by a far greater PK variability than intravenous agents [43].
Regardless CDKis are oral drugs characterized by a similar PK profile, palbociclib and ribociclib
show different features from abemaciclib. These peculiarities influence their therapeutic use in terms
of schedule of administration and dose adjustments, according to PK details reported in Table 3.
Palbociclib and abemaciclib are slowly absorbed [44], whereas ribociclib is more rapidly absorbed
compared with palbociclib and abemaciclib [39].
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Table 2. Summary of more relevant adverse events (grade 3 or 4 according to NCI-CTCAE) in registration trials of palbociclib, ribociclib and abemaciclib. CDKi,
CDK4/6 inhibitor; ET, endocrine therapy; AI, aromatase inhibitors.
CDKi Registration Trial ET Backbone
Patients Reporting Adverse Events with Grade 3 or 4 of (%)
Neutropenia Leukopenia Anemia Infections Nausea Vomiting Diarrhea Fatigue
Palbociclib
PALOMA-2 AI 66.5 24.8 5.4 0 0.2 0.5 1.4 1.8
PALOMA-3 Fulvestrant 76.1 33.8 2.8 3.2 0 0 0 0
Ribociclib
MONALEESA-2 Letrozole 59.3 21 1.2 4.2 2.4 3.6 1 2.4
MONALEESA-3 Fulvestrant 57.1 15.5 3.9 7.7 1.4 14.1 0.6 1.7
Abemaciclib
MONARCH-1
(monotherapy) - 28.9 27.7 0 - 4.5 1.5 19.7 12.9
MONARCH-2 Fulvestrant 26.5 7.3 5.8 4.9 0.9 1.2 13.4 1.8
MONARCH-3 AI 23.8 8.6 7 - 1.2 1.5 9.5 1.8
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Table 3. Summary of pharmacological properties of palbociclib, ribociclib and abemaciclib in detail.
Pharmacological Features Palbociclib [45] Ribociclib [10] Abemaciclib [46]
Dosage and schedule 125 mg/daily day 1–21 Q28 with food 600 mg/daily day 1–21 Q28 200 mg twice daily in monotherapy; 150 mg twice daily incombination with endocrine therapy
Selectivity CDK4 = CDK6 [27] CDK4 > CDK6 [28] CDK4 >> CDK6; low potency to CDK1, CDK7 and CDK9 [31]
Lipophilicity;
BBB penetration cLogP value of 5,5; + [47] N.A. cLogP value of 2.7; +++ [47]
PK
Cmax: 52 ng/mL
Tmax: 7 h
t1/2: 25.9 h
Vd: 2793 L
AUC 0–10 (ng/mlxh): 299 [48]
Cmax: 1000 ng/mL (higher value for Asiatic people)
Tmax: 5 h
t1/2:32.6 h
Vd: 1090 L
AUC 0–24 (ng/mlxh): 20000 [24,49]
Cmax: 298 ng/mL
Tmax: 8 h
t1/2: 8 h
Vd: 690.3 L
AUC 0–24 (ng/mlxh): 5520
Bioavailability 46% N.A. 45%
Binding protein 85% 70% 96–98%
Metabolism Hepatic: substrate of CYP3A and SULT2A1 [48] Hepatic: substrate of CYP3A4 Hepatic: substrate of CYP3A4
Excretion
In feces 74% 69.1% 81%
In urine 17% 22.6% 3.4%
Effect on ADME enzymes +
autoinhibition
Weak and time-dependent inhibitor of CYP3A.
Palbociclib is a substrate of P-gp and BCRP and
inhibits OCT1. [7]
Moderate/strong dose- and time-dependent inhibitor of
CYP3A4. Ribociclib is a substrate of P-gp. Reversible
CYP1A2, 2E1 inhibitor. Potentially inhibits P-gp, BCRP,
OATP1B1, OATP1B3, OCT1, OCT2, BSEP and MATE1.
Abemaciclib is a substrate of P-gp and BCRP and inhibits OCT2
and MATE
Active metabolites No [40] No Yes: N-desethylabemaciclib (M2), hydroxyabemaciclib (M20),hydroxy-N-desethylabemaciclib (M18)
Food intake alteration Absorption and drug exposure lower in fastedstate [40] No High fat and high caloric meal increase AUC (9%) and Cmax (26%)
Adverse events Neutropenia G3/4 Nausea any grade Diarrhea any grade; Fatigue any grade. Neutropenia(rare and manageable)
Effect of co-administered CYP3A
inhibitors
↑87% AUC
↑34% Cmax
Strong inhibitors: ↑3.2-fold AUC and ↑1.7-fold Cmax;
Moderate inhibitors: ↑1.9-fold AUC and ↑1.3-fold Cmax
(after a single 400 mg dose)
Strong inhibitors: ↑237% AUC (↑119% of the active metabolites)
and ↑30% Cmax (↑7% of the active metabolites)Moderate
inhibitors: ↑1.7-fold AUC (↑1,3-fold of the active metabolites)
Effect of co-administered CYP3A
inducers
Strong inducers: ↓85% AUC and ↓70% Cmax;
Moderate inducers: ↓32% AUC and ↓11% Cmax [7]
Strong inducers: ↓89% AUC
↓81% Cmax
Moderate inducers: ↓60%AUC
↓37% Cmax
(after a single 600 mg dose)
Strong inducers: ↓67% AUC of parent drug and active metabolites
Moderate inducers: not known
Pediatric use No data No data No data
Geriatric use No differences on safety and efficacy No differences on safety and efficacy No differences on safety and efficacy
PK—pharmacokinetics; CDKs—Cyclin-dependent kinases; AUC—Area Under the Curve; Cmax—the highest concentration in blood; Tmax—the time a drug takes to reach its peak in blood
concentration; t1/2—drug half-life; Vd—Volume of Distribution; cLogP value—logarithm of a drug partition coefficient between n-octanol and water log; BBB,—Blood Brain Barrier; Day
1–21 Q28—once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.
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Palbociclib, ribociclib, and abemaciclib are substrates of P-glycoprotein (P-gp; ABCB1) and breast
cancer resistance protein (BCRP; ABCG2). They are both efflux transporter proteins which are localized
in important anatomical structures such as blood brain barrier (BBB), proximal tubule cells, enterocytes,
and hepatocytes [50]. These transporters play an important role in the first-pass elimination of
orally administered drug influencing their bioavailability in the intestine by (a) effluxing them at
the lumen-facing epithelia of the small intestine and colon, and the bile-facing canaliculi of the liver,
(b) excreting from the systemic circulation at the urine-facing side of the brush border membrane
of proximal tubules in the kidney and by (c) modifying their therapeutic concentration in different
target tissues as in BBB. In particular, in vitro studies suggest that palbociclib and abemaciclib are
substrates of P-gp and BCRP at the BBB, affecting their passage through, while ribociclib is mainly
substrate for intestinal P-gp, which may possibly affect its oral absorption rate rather than its brain
concentration [50–52]. Regardless, recent data from in vivo experimentation suggest for ribociclib
a more similar profile to other CDKis as substrate of P-gp at the BBB [53]. In particular, due to the
peculiar lipophilicity properties, palbociclib and abemaciclib easily penetrate the BBB, but compared
to palbociclib and ribociclib only abemaciclib achieves and maintains the therapeutic concentration at
lower doses [51,54]. This favorable profile in central nervous system (CNS) can be also explained by the
dose-related inhibiting effect of abemaciclib on P-gp and BCRP. On the contrary, palbociclib [51] and,
from recent in vivo evidences, ribociclib [53] appears to be abundantly removed from cerebrospinal
fluid. In vitro data suggest also that palbociclib and ribociclib may inhibit intestinal P-gp and BCRP
with a possible increase in the drug absorption into the bloodstream. No evidence of such an interaction
is available in vivo [50].
Inter- and intra-patient variability after administration of CDKis represents a relevant issue for
these compounds, especially for ribociclib [11,55]. Ribociclib is not influenced by food intake nor
gastric pH changes, differently from palbociclib and abemaciclib [55]. Palbociclib variability has been
reported to be reduced on fed state [11,56]. In the registration clinical study [45], 13% of all patients with
palbociclib administration under fasting conditions revealed a lower palbociclib exposure. A study
conducted on healthy volunteers showed a higher Cmax in subjects who assumed palbociclib with a
high fat meal. This is probably due to the dissolution of palbociclib capsule that is highly dependent
on pH with an inverse relationship. Abemaciclib is characterized by an extensive variability in cancer
patients, independently from demographics (sex, age, body weight). Data from healthy subjects show
that increasing the dose and/or duration of abemaciclib treatment results in a reduction in the fraction
of dose absorbed [57]. Food intake slightly modifies abemaciclib PK profile without relevant clinical
consequences; although high fat and high caloric meal increases AUC by 9% and Cmax by 26%. Overall
PK variability of abemaciclib is not meaningfully influenced by food-effect [16,57].
Palbociclib and ribociclib have a moderate binding to human plasma proteins and a high volume
of distribution (Vd) [49], on the contrary abemaciclib is highly bound to plasma proteins and thus it is
characterized by a lower Vd.
All three drugs undergo hepatic metabolism, being metabolized by the CYP3A4 [50]. Ribociclib
is characterized by the longest half-life among CDKis and its toxicity profile prevents a continuous
schedule [29,58] as also for the case of palbociclib [45]. Abemaciclib can be instead administered
continuously [2,15,57,59].
Palbociclib has shown a proportional dose accumulation, influencing Cmax and AUC values and
has a dose-independent PK when administered in a single dose. Since it is a weak time-dependent
inhibitor of a CYP3A4, palbociclib PK is expected to be dose dependent in multiple dose conditions, due
to the inhibition of its own metabolism. On the contrary, ribociclib has a non-linear PK and is a strong
CYP3A4/5 time-dependent inhibitor when administered at a 600 mg dose, and a moderate CYP3A4
inhibitor at a 400 mg dose. Ribociclib reversibly inhibits also CYP1A2 and CYP2E1. Abemaciclib and
its major active metabolites have been proven to downregulate mRNA of CYPs, including CYP1A2,
CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP3A4.
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Palbociclib, ribociclib, and abemaciclib have not been studied in pregnancy, but several in vivo
studies show teratogenic issues and their use is not recommended in this clinical setting and during
lactation [11,16,46].
2. Potential Drug-Drug Interactions
2.1. Potential Drug-Drug Interactions with ADME
Hereinafter the potential DDIs based on the most common comorbid conditions will be
summarized. Meaningful clinical drug interactions have been extensively described, according
both to the results from the consensus workshop [50] on medication that can be safely administered
concomitantly with palbociclib, ribociclib and abemaciclib and to each FDA leaflet [10,45]. DDIs with
abemaciclib have been described using the information contained in the leaflet [46] and by analogy
with the other CDKis. The list of all drugs major substrate for CYP3A4, sensitive or with narrow
therapeutic index (NTI), is reported in Table S1.
2.1.1. Agents That May Alter CDK4/6 Inhibitors Absorption
Drug absorption from the gut could be source of intra- and inter-patient variability as well as PK
variability. Absorptive surface area, transit time through the gut, blood flow to the site of absorption,
and gastric and intestinal pH are among the factors influencing the absorption [43].
(1) Gastric pH Elevating Medications
The most frequent interactions affecting absorption, and thus drug bioavailability, are due to
gastric pH modification perpetrated by proton pump inhibitor (PPIs), H2-receptor antagonists or local
antacids [50]. The effect of acid-reducing agents on CDKis was only studied in palbociclib. Two clinical
trials performed in healthy subjects found that co-administration of a single dose of palbociclib with
multiple doses of the PPI rabeprazole decreased palbociclib Cmax by 41% and 62% under fed and fasted
conditions, respectively. The AUC decrease was instead relevant only in the fasted state (80% vs. 13%
in the fed state). Thus, considering that local antacids and H2-receptor antagonists are less efficacious
than PPIs in reducing gastric acidity, the effect of drug elevating gastric pH is expected to be minimal
on fed state. Nonetheless, concomitant use PPIs should be avoided with palbociclib. No DDIs are
expected with PPIs, H2-receptor antagonists, or antacids with ribociclib and abemaciclib that can be
taken with or without food.
(2) Membrane Transporters
Besides being inhibitors, ribociclib and abemaciclib are also substrate of P-gp and BCRP while
palbociclib it is not in most tissue (except for BBB). DDIs are expected from competition with other
substrates for these membrane transporters. However, as reported in Section 2.1.4, guidelines on
management of such interactions are still lacking.
2.1.2. Agents That May Alter CDK4/6 Inhibitors Distribution
Plasma protein binding can have multiple effects on both PK and PD of a drug. Only free drug
can produce the therapeutic effect because it can be distributed to the site of action and interact
with receptors. Competitive displacements are the predominant interactions among protein binding
reactions that results in increased free plasma concentration of the displaced drug. Because palbociclib
and ribociclib are not highly protein bound (palbociclib 85% and ribociclib 70%) distribution related
DDIs are not expected. Regardless, the mean bound fraction of abemaciclib was found to be 96.3%,
93.4% for M2, 96.8% for M18, and 97.8% for M20, its active metabolites. For drugs highly bound
to plasmatic proteins, displacement reactions may acquire clinical importance. Future studies are
warranted to evaluate and monitor the effects of these potential DDIs.
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2.1.3. Agents That May Alter CDK4/6 Inhibitors Metabolism
Metabolism of all CDKis could be impacted to a various extent by strong to moderate inhibitors
and inducers of CYPs of which they are substrate. Palbociclib, ribociclib, and abemaciclib undergo
extensive CYP3A-mediated hepatic metabolism.
(1) CYP3A Inhibitors May Increase CDK4/6 Inhibitors Plasma Concentrations
In the FDA leaflet it is recommended to avoid the concomitant use of strong CYP3A inhibitors
(e.g., clarithromycin, protease inhibitor for HIV and HCV, itraconazole, ketoconazole, posaconazole,
voriconazole, ritonavir, saquinavir, grapefruit) because of the increase in the recorded CDKis plasma
exposure that may lead to increased toxicity [10,45,46]. Particularly, plasma exposure of abemaciclib
and its active metabolites is increased to a clinically meaningful extent when administered with strong
CYP3A inhibitors. Strong CYP3A4 inhibitors when co-administered with CDKis may also lead to an
enhanced risk for prolonged QT interval as well (see Section 2.2.). If an alternative with less potential for
CYP3A inhibition could not be considered, the dosage of the CDKis needs to be reduced to 75 mg/day
(↓40%) for palbociclib, to 400 mg/day (↓33.33%) for ribociclib and to 100 mg twice a day (↓50/33.33%) for
abemaciclib. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions,
the abemaciclib dose should be further reduced to 50 mg twice daily when concomitantly used with
other strong CYP3A inhibitors. If the strong inhibitor is discontinued, after five half-lives of the
inhibitor, the dose of CDKis could be increased to the dosage used prior the introduction of the inhibitor.
With regard to moderate inhibitors (e.g., erythromycin, ciprofloxacin, fluconazole, isavuconazole,
aprepitant, netupitant, nifedipine, nicardipina, verapamil, ziprasidone) a risk of increased CDKis
exposure is possible, although, at present only data regarding abemaciclib and ribociclib are available
(see Table 3). In the FDA leaflet, it is recommended to monitor a possible increased toxicity, while for
weak inhibitors (e.g., ticagrelor, cilostazol, fosaprepitant, alprazolam), only a low risk of increased
exposure is reported [10,45,46]. Dose adjustment suggestions are summarized in Table 4.
Table 4. Dose adjustments suggestions according to concomitant medications and clinical features.
Day 1–21 Q28, once daily for 21 consecutive days followed by 7 days off treatment to comprise a
complete cycle of 28 days.
Concomitant Medications or
Pathophysiological Conditions
Palbociclib 125 mg
Once a Day,
Day 1–21 Q28
Ribociclib 600 mg Once a Day,
Day 1–21 Q28
Abemaciclib 150 mg Twice Daily in
Combination with Endocrine Therapy;
200 mg Twice Daily in Monotherapy.
Continuous Schedule
Strong CYP3A inhibitor Avoid. If unavoidable: 75mg/day starting dose (↓40%) *
Avoid. If unavoidable: 400
mg/day starting dose (↓33.33%) *
Avoid. If unavoidable: 100 mg twice
daily starting dose (↓50/33.33%) *
Moderate CYP3A inhibitor Monitoring Monitoring Monitoring
Weak CYP3A inhibitor Low risk of DDI Low risk of DDI Low risk of DDI
Strong CYP3A inducer Avoid. Consider an alternative Avoid. Consider an alternative Avoid. Consider an alternative
Moderate CYP3A inducer Monitoring Monitoring Monitoring
Weak CYP3A inducer Low risk of DDI Low risk of DDI Low risk of DDI
Hepatic impairment
recommendation
Child-Pugh A or B: no
modifications
Child-Pugh C: 75 mg/day
starting dose
Child-Pugh A: no modifications
Child-Pugh B or C: 400 mg/day
starting dose
Child-Pugh A or B: no modifications
Child Pugh C: 150 mg/day starting dose
Renal impairment
recommendation
Mild to moderate:
no modifications
Severe or hemodialysis:
no data
Mild to moderate:
no modifications
Severe: lower starting dose to 400
mg/day (EMA) or 200 mg/day
starting dose (FDA)
Mild to moderate: no modifications
Severe or hemodialysis: no data
DDI—Drug-drug interaction. * The reduction must be maintained during the treatment with the inhibitor and at
least five half-lives of elimination after its withdrawal.
Available data on changes in PK parameters in healthy subjects for each CDKi following
co-administration with strong and moderate inhibitors are reported in Table 3, while the most used
CYP3A inhibitors were reviewed and classified by drug interaction risk potential in Table S1.
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(2) CYP3A Inducers May Decrease CDK4/6 Inhibitors Plasma Concentrations
Co-administration of strong CYP3A4 inducers decreases CDKis plasma exposure and may lead
to reduced activity and drug failure. As CYP3A strong inhibitors, strong inducers (e.g., phenytoin,
rifampin, carbamazepine, phenobarbital, and St John’s Wort) should be avoided and an alternative
with less potential to induce CYP3A4 is recommended. The effect of moderate CYP3A inducers
(e.g., efavirenz) on the PK of CDKis has been studied only on palbociclib and ribociclib. It is
recommended in the FDA leaflet to monitor a possible increased risk of decreased exposure and a lack
of efficacy [10,45,46]. There is a low risk of decreased exposure of CDKis for co-administration with
weak inducers (e.g., nevirapine, dexamethasone, oxcarbazepine, clobazam).
Available data on changes in PK parameters recorded in healthy subjects for each CDKi following
co-administration with strong and moderate inducers are reported in Table 3, while the most commonly
used CYP3A inducers were reviewed and classified by potential drug interaction risk in Table S1.
2.1.4. Agents That May Be Altered by Co-Administration with CDK4/6 Inhibitors
When CYP3A4 major substrates are concomitantly administered with CDKis, their serum
concentration could be increased by virtue of CDKis inhibitory potential on CYP3A4, and a dose
reduction may be warranted especially with ribociclib (see Section 1.3).
Caution is recommended especially when the co-administered drugs besides being CYP3A4
major substrate are also characterized by a NTI and/or are sensitive substrate drugs where small
variations of drugs can cause toxicity (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine,
everolimus, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, simvastatin, and atorvastatin;
see Table S1). Sensitive substrates are defined by FDA as substrates that can induce a five-fold or
greater increase in AUC with strong index inhibitors while moderately sensitive substrates, when
the increase in AUC is two-fold or greater to less than five-fold. Co-administration of midazolam in
healthy subjects with multiple dose of either palbociclib or ribociclib 400 mg and 600 mg increased
midazolam plasma exposure of 61%, 3.8-fold and 5.2-fold, respectively, compared to the administration
of midazolam alone [10,45]. Caution may be necessary also when abemaciclib, highly protein bound,
is co-administered with drug with NTI. The displacer drug may produce a rapid increase in plasma
concentration of the displaced medication possibly leading to enhanced pharmacological effect and/or
toxicity. Nevertheless, there are no guidelines on how to tackle these types of interactions.
The list of all drugs major substrate for CYP3A4, sensitive or NTI for which a dose adjustment
could be considered according to Bellet et al. [50], is shown in Table S1.
Other DDIs described with CDKis results from competition for the membrane transporters.
Caution should be exercised for CDKis co-administration with metformin, which is a relevant substrate
of renal OCT2, MATE1, and MATE2-K transporters because of the risk of reduced renal clearance and
secretion of metformin. Furthermore, at clinically relevant concentrations, it has been shown that
palbociclib in vitro potentially inhibits intestinal OCT1 along with intestinal P-gp and BCRP. Moreover,
ribociclib potentially inhibits OATP1B1/B3, OCT1, OCT2, BSEP, and MATE1 along with P-gp and BCRP,
while abemaciclib and its major active metabolites inhibit OCT2, MATE1, and MATE2-K, along with
P-gp and BCRP. Although no data are available yet, it may be hypothesized that, at therapeutic doses,
CDKis enhance toxicity risk of drugs that are substrates for P-gp due to the inhibition of the efflux
pump and with a consequent increase in their plasmatic concentration.
2.1.5. Pain Killer (Opioids and NSAIDs)
According to the International Association for the Study of Pain, pain prevalence in breast
cancer varies from 40% to 89%. Pain control represents indeed one of the greatest challenges in
patients with cancer. The most commonly used drugs for pain control were reviewed and classified
by drug interaction risk potential in Table S1. Reported high risk DDIs involve major CYP3A4
substrate/NTI drugs.
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2.2. Potential Drug-Drug Interactions with Non ADME Agents That May Potentiate CDK4/6 Inhibitors
Toxicity
The meaningful DDIs that will be hereinafter reviewed concern CDKis mechanism of action
rather than their ADME profile. As mentioned in our Safety Section 1.2., ribociclib has a special
warning for electrophysiological toxicity, suggesting a careful monitoring and a dose interruption,
discontinuation, or a dose modification [11]. Drugs with a known potential to prolong QT such as
antiarrhythmic medicines (including, but not limited to amiodarone, disopyramide, procainamide,
quinidine and sotalol) and other drugs that are known to prolong the QT interval (including, but not
limited to, chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, bepridil,
pimozide and ondansetron) could also increase the risk of palbociclib and abemaciclib for QT
prolongation interval.
Differently from palbociclib and abemaciclib, MONALEESA-2 trial showed that patients assuming
ribociclib reported more events of QT prolongation, independently from concomitant therapies [60].
In this regard, Table S1 reports a differential risk for prolonged QT interval deriving from DDIs between
palbociclib, abemaciclib and ribociclib.
Antidepressant
Antidepressant treatment is often useful in patients with breast cancer to treat anxiety and
stress-related disorders and is also indicated for specific symptoms such as insomnia (mirtazapine and
trazodone), neuropathic pain (duloxetine and amitriptyline), hot flashes (venlafaxine and SSRIs), lack of
appetite, nausea and/or vomiting (mirtazapine) and fatigue (bupropion and methylphenidate). A major
concern is the effect of antidepressants on QTc interval prolongation and the risk of Torsade de Pointes
(TdP). Citalopram and escitalopram prolong QTc and present known risk of TdP, while mirtazapine
and venlafaxine with possible risk for TdP. DDIs with CDKis exist for most antidepressants, either via
CYP3A4 or mostly via QTc prolongation.
The most commonly used antidepressants were reviewed and classified by drug interaction risk
potential in Table S1.
2.3. Other DDIs
2.3.1. Osteoporosis Treatment (Denosumab, Vit D)
Denosumab is not expected to alter the PK of medicinal products metabolized by CYP3A4.
Vitamin D supplementation could play a role considering that when systemic (or even local) VitD3
levels fluctuate, the disposition of the drugs that serve as CYP3A4 substrates may be changed [61].
2.3.2. Potential SULT2A1-Mediated DDIs with CDK4/6 Inhibitors
Even though sulfotransferases (SULTs) enzymes are involved in the metabolism of many
xenobiotics, there are few documented examples of DDIs involving these enzymes, also considering
the overlapped substrate selectivity reported among different isoforms of SULTs enzymes [62].
Some drugs have demonstrated to regulate SULT gene expression by interacting with members
of the nuclear receptor (NR) superfamily (i.e., methotrexate through interaction with constitutive
androstane receptor, CAR; genistein through liver X receptor, LXR; estradiol through estrogen receptor
alpha, ERα; dexamethasone by activating pregnane X receptor transcription factor (PXR) and fibrates as
proliferator-activated rector alpha agonists, PPARα agonists). This could lead to an increased first-pass
effect with consequent reduction in drug levels and possible loss of efficacy [62,63].
SULT2A1 is inhibited in vitro by testosterone, clomiphene, danazol, spironolactone, cyproterone
and chlorpromazine. Inhibition of SULTs may reduce metabolism of drugs, leading to increased drug
levels and possible toxicity [62,63].
The non-steroidal anti-inflammatory drug (NSAID) colecoxib has shown to modulate the activity
of SULT2A1 by causing product switching for estradiol sulfonation and increasing overall estrogen
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sulfonation with a potential benefit for breast cancer patients in reducing active estrogen [62]. Potential
SULT2A1-mediated DDIs with CDKis are of uncertain clinical relevance nor are supported by strong
scientific evidences.
3. Potential Drug-Gene Interactions with ADME
All CDKis are metabolic substrates for CYP3A enzymes, CYP3A4 and CYP3A5 and consequently
their pharmacogenomic profile assessment could be an important factor to be considered along
with DDIs. Moreover, they are transported via ATP-Binding Cassette (ABC) transporters that were
reported to affect their absorption, elimination, and distribution in the body compartments. Several
single-nucleotide polymorphisms (SNPs) have been identified in the genes encoding for CYP3A4,
CYP3A5 and P-gp to contribute in drug metabolism. Pharmacogenomic is the discipline studying
patients’ SNPs and their relationship with the therapy outcome and is one of the approaches used
to address the issue of inter-patient variability. The study of the genetic variability in ADME-related
genes such as cytochrome or membrane transporters has been considered an effective strategy to
tailor pharmacological treatments. However, it is widely acknowledged that the patient’s phenotype
regarding drug ADME is not only the result of the patients’ genotype but also of a plethora of
pharmacological, physiological, pathological, and environmental factors. Although no data are
available on DGIs regarding CDKis, many studies have been published concerning the impact of
genetic polymorphism in CYPs and transporters for many other drugs. By analogy, it can be speculated
that polymorphisms on both cytochromes and transporters involved in CDKis ADME might be relevant
as well. Evaluating the still unexplored aspect of DGIs, along with DDIs, in CDKis could be a valuable
tool in predicting drug PK variability, especially considering the effect seen in specific population [18].
According to some authors, a different prevalence of CYP3A4 SNPs between Asian and non-Asian
populations could be a possible explanation for the heterogeneity in CDKis efficacy and tolerability
profile seen in the recent aggregate data meta-analysis on 2499 patients (n = 492 Asians; n = 2007
non-Asians) [18,19]. The most relevant SNPs possibly affecting CDKis ADME (CYP3A4, CYP3A5,
ABCB1, and ABCG2) will be hereinafter reviewed.
3.1. Phase I Enzymes: CYP3A4 and CYP3A5
The human CYP3A plays a dominant role in the metabolism of more drugs than any other
biotransformation enzyme. CYP3A subfamily is the predominant isoform in both the intestinal
epithelium and liver. Genes coding for CYP3A are clustered in the same locus on chromosome 7 and
linkage results [64] demonstrated a high degree of sequence homology and substrate overlap specificity
between CYP3A4 and CYP3A5. CYP3A expression varies as much as 40-fold in liver and small intestine
donor tissues [65]. Increasing evidences have shown that genetic variants in both CYP3A4 and CYP3A5
could contribute to the large interindividual variability in CYP3A enzyme expression and activity and
ultimately affect response to substrate drugs [66,67]. In the human liver, CYP3A4 accounts for most
CYP3A isoform while CYP3A5 is not uniformly present and might be expressed in only 20–30% of
people [43]. Over time, few SNPs have shown to affect CYP3A4 expression or activity contrarily to
other highly polymorphic CYP3A enzymes (2D6, 2C9 and 2C19).
CYP3A4*22 is an intronic SNP located in intron 6 (rs35599367), first reported in 2011 to be
responsible of reduced mRNA/protein expression in the C > T variant [68]. Regardless the underlying
mechanism is still unknown, CYP3A4*22 is considered so far, the only variant clearly associated with
CYP3A4 reduced activity up to 50%. Several studies tested the effect of CYP3A4*22 on PK of drugs.
A significant impact of CYP3A4*22 was found on the oncologic tamoxifen [69,70] and sunitinib [71]
and not in clopidogrel [72] and tacrolimus [73] metabolism. The relevance of CYP3A4*22 has been
hypothesized to be even more enhanced in subjects having no active CYP3A5 enzyme (as most
Caucasian individuals). Its allele frequency ranges from 5–8% in Caucasian to 4% in Asian and African
population but nonetheless it was shown to be clinically relevant. Regardless CYP3A4*1B (-392A>G,
rs2740574) is the most studied SNP, its functional significance is still considered controversial nowadays
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and it has been hypothesized that the true cause of the observed clinical phenotype was imputable
to the linkage disequilibrium between CYP3A4*1B and another CYP3A allele (CYP3A5*1 in Africans
and *3 in Caucasians) [67,74]. Other variants have been described in non-exonic regulatory regions,
and most of them have no functional significance.
Rare variants may contribute to explain effect on PK observed in the clinic and, especially in
drug metabolism, they could provide a promising new approach to explain the observed variation in
overall drug response not justified by common SNPs. Novel techniques as next generation sequencing
(NGS) are extremely helpful tools in this context. It has been suggested that NGS detection of copy
number variations (CNV) of genes involved in ADME of drugs could contribute to further improve
genotype-phenotype correlations [75]. Plus, exome sequencing can accelerate pharmacogenetic
discovery by assessing both common, i.e., minor allele frequency (MAF) > 5%, and rare (MAF < 1%)
variation in virtually all genes in an individual at relatively low cost [76,77].
The only variants identified as causing loss-of-function-mutations and resulting in complete loss of
CYP3A4 protein formation were two exonic rare variants: *20 rs67666821 [78] and *26 rs138105638 [79].
Both CYP3A4*20 and *26 caused a premature stop codon yielding a truncated protein devoid of
catalytic activity. The first *20, was carried in heterozygosis by a Brazilian woman (calculated MAF in
Caucasian population <0.006) while the other, *26, was found in homozygosis in a kidney transplanted
patient with Alport syndrome. This latter patients carried also nonfunctional CYP3A5 (*3/*3 genotype)
resulting the first case known to date with complete failure of CYP3A enzyme activity.
No guidelines are published to date on DGIs involving CYP3A4 nor on how to translate CYP3A4
genotype to phenotype. However, based on the current evidences, CYP3A4 poor metabolizer (PM)
status can be defined by the presence of aforementioned loss of function rare variants. Individuals
with one copy of the CYP3A4*22 allele will have the predicted phenotype of normal/intermediate
metabolizers (NMs/IMs, respectively) while individuals with two variant copies can be considered
IMs. Individuals without any *22 variant will therefore be NMs.
CYP3A5*3 (rs776746) is the most extensively studied CYP3A5 SNP and it confers a variant in
intron 3, leading to aberrant splicing and nonfunctional CYP3A5. Its allele frequency varies from
approximately 50% in African-Americans to 90% in Caucasians. Additional and less frequent variations
as CYP3A5 *6 (mainly in African 15–25%) and *7 (Asians 1%) have been associated with decreased
CYP3A5 activity, similar to the one observed with *3. Several other CYP3A5 variants have been
described but occur at relatively low allelic frequencies and their functional significance has not
been established yet. The CYP3A5*1 allele produces the functional protein (defining the expresser
phenotype and normal metabolizer, NM), whereas the common CYP3A5*3 allele together with *6
and *7 will identify the nonexpresser phenotype. Specifically, an individual carrying one functional
allele and one nonfunctional allele are IMs while an individual carrying two nonfunctional alleles will
be PMs. Guidelines have been published by CPIC regarding tacrolimus dose-adjustment based on
the evidence that individuals with the expresser phenotype may require higher dose compared with
nonexpressers [80].
3.2. Phase II Enzymes: SULTs
Sulfate conjugation catalyzed by cytosolic SULTs enzymes is an important pathway in the
biotransformation of many drugs, neurotransmitters, and steroid hormones. SULTs enzymes display
a wide interindividual variability, even though its clinical impact on drug adverse effects and
efficacy has not been elucidated yet [63]. Such variability was only partially explained by genetic
variation, suggesting that other non-genetic, epigenetic, and environmental influences could be major
determinants of variability in SULT activity [62].
SULT2A1 is a member of this family of enzymes and is highly expressed in the human liver,
adrenal cortex, and lastly small intestine [62]. Among endogenous compounds are listed steroids
(androsterone, allopregnanolone, dehydroepiandrosterone) and bile acids.
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Ethnic-specific pharmacogenetic variants in SULT2A1 might influence the biotransformation of
both orally administered agents and/or endogenous substrates. SNPs and CNVs have been proposed as
a source of genetic variability in SULT2A1 encoding gene. Two SULT2A1 SNPs (rs2637125 and rs182420)
altering the amino acid sequence [81] and one CNV resulting in a deletion/insertion of a non-coding
2849bp [82] have been identified and associated with altered SULT2A1 activity. These variants
may contribute to individual variation in response to drugs, however current knowledge on SULT
interindividual variability is based on in vitro/in vivo pharmacogenetic and expression/activity study.
Studies in humans are lacking [63].
3.3. Impact of Genes with Indirect Impact on CYP3A Activity
Variations in the CYP3A4/5 genotype contribute only to a minor extent to the interindividual
differences while a major cause of variability could derive from NRs, cytokines or competitive inhibition
of the CYP3A-mediated drug metabolism. Variants in genes as NR1/2, PPARα and P450 oxidoreductase
(POR) have been lately identified to have an indirect impact on CYP3A activity. Variants also in PXR
and vitamin D receptor (VDR) could play a role in CYP3A4 induction [61,83,84]. A few clinical studies
have reported higher tacrolimus dose requirement, indicating elevated metabolic activity of the CYP3A,
in association with NR1/2 rs2276707 and with POR*28 rs1057868 [85]. In this latter case the noted effect
was only in patients CYP3A5 expresser. While CYP3A4 mRNA expression was significantly reduced
in cells derived by patients’ homozygous carriers of PPARα rs4253728 [67].
Members of the NR family (farnesoid X receptor, FXR; CAR; PXR and ERα) are important regulator
of SULT2A1 transcription as well.
3.4. Transporters (ABCB1 and ABCG2)
Despite evidence for interindividual variability in ABCB1 expression and function, so far, all
ABCB1 described SNPs have not shown consistent association neither with drug PK nor PD. The three
most studied variants in ABCB1 are two synonymous SNPs, 1236C > T, (rs1128503) in exon 12 and
3435C > T (rs1045642) in exon 26; and one non-synonymous SNP, 2677G > T/A (rs2032582 in exon 21).
These SNPs are in high LD [86] defining ABCB1*13 haplotype and have been observed in most ethnic
groups. Considering the controversial results obtained so far, no adjustment in drug dosing have been
recommended for individuals carrying sequence variants of ABCB1 and further studies are warranted
to draw any conclusion. However, considering that the presence of these variants has been associated
with a lower P-gp expression [87] it could identify an ineffective efflux pump functionality phenotype
with the consequence on bioavailability of orally administered CDKis.
As per P-gp also BCRP, encoded by ABCG2 gene, is an efflux transporter responsible of limiting
oral drug bioavailability of many common medication and transport across tissue-brain barriers.
It is localized in the gastrointestinal tract, liver, kidney, mammary tissue, placenta, testes, and brain
endothelium. SNPs on ABCG2 have demonstrated to be closely related to interindividual variability
in therapeutic response. The two most common missense variants are c.34G>A (rs2231137) and
c.421C>A (rs2231142). According to several studies, the c.34G>A variant has no appreciable effect
on the expression or function of the transporter while c.421C>A was shown to reduce expression of
BCRP and result in lower efflux of substrates. Both SNPs have a higher allele frequency in East Asians
(30–60%) compared to Caucasians and African-American (5–10%). ABCG2 c.421C>A genotype was
found to be a significant determinant of imatinib [88], gefitinib [89] and sunitinib [90] PK in cancer
patients. Regarding erlotinib, the same association, with consequence on toxicity risk, was found to be
significant only in Asian patients [91,92].
4. Phenoconversion
According to some authors, the reason of the conflicting results often observed in DGIs association
studies, lies in the lack of consideration of DDIs and/or other pathophysiological features that impact
drug metabolizing enzyme activities. Phenoconversion is a phenomenon that occurs when genotypic
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NMs are converted into phenotypic IMs or even PMs of drugs, with a modification of their clinical
response to that of genotypic PMs [25]. While genotype-predicted PMs (based on the detection of
two no-function or severely reduced-function alleles) reliably predicts a PM phenotype, the same
cannot be claimed for individuals with genotypes predicting NMs/IMs phenotype. Pharmacogenetic
studies do not focus on the prevalence of genotype–phenotype discordance in non-PM subjects [25].
This is an issue for the appropriateness of genotype-based prescribing decisions in non-PM subjects.
Two main factors of phenoconversion involves co-medications that inhibit or alter the activity of a
drug metabolizing enzymes, or pathophysiological features associated with co-morbidities that impact
expression levels of drug metabolizing enzymes [25]. In cancer treatment phenoconversion, due both
to genetic polymorphisms and clinical alterations induced by tumor itself, plays a key-role in the
efficacy of therapies. Phenoconversion has the potential to influence pharmacological properties of
employed drugs in terms of PK parameters, especially AUC and Cmax, concurring to the interindividual
variability often seen among healthy subjects and patients [25,43,93].
An example of phenoconversion induced by DDIs consists in the potent CYP2D6 inhibitor
paroxetine that is often prescribed with the CYP2D6-activated tamoxifen as tamoxifen-induced
hot flushes treatment along with depression treatment. According to some authors, CYP2D6 PM
genotype could not be significantly associated with an increased risk of tamoxifen failure because
of the lack of concern toward CYP2D6-related DDIs. Such interactions could help identify a higher
number of CYP2D6 PMs phenoconverted from NM, IM, or even ultra-rapid metabolizers (UMs) status.
According to a population-based cohort study published last year, paroxetine use during tamoxifen
has been associated with an increased risk of death from breast cancer directly related to the extent of
co-prescribing, supporting the hypothesis that paroxetine can reduce or abolish the benefit of tamoxifen
in women with breast cancer [94]. When 75% of the time on tamoxifen was overlapped with paroxetine,
the adjusted hazard ratio (adjHR) for survival was 1.91, when 50%, the adjHR was 1.54, while when
25%, the adjHR was 1.24.
5. Potential Drug-Pathophysiological Interactions
Many clinical conditions as cancer and cardiovascular diseases are known to have inflammatory
components, potentially influencing the activity of drug metabolizing enzymes. Besides inflammation,
other clinical conditions (e.g., hepatic or renal impairment) or pathophysiological conditions as gender,
women’s hormonal status, obesity and age have been hypothesized to modify cytochromes activities.
5.1. Hepatic Impairment
Hepatic impairment can affect drug disposition and metabolism according to the underlying
liver disease and its severity. Severe hepatic diseases, up to cirrhosis, can reduce hepatic clearance,
metabolism and drug bioavailability through different mechanisms such as: (i) the capillarization of
the sinusoids, consisting in the occlusion of the fenestration of sinusoidal endothelium which limits
the drug uptake from the hepatocyte [95,96]; (ii) the overall inadequate hepatic enzymatic activities;
(iii) the reduced production of plasma proteins.
For patients with mild to moderate hepatic disease, no dose adjustment is required, while in the
case of palbociclib, patients with severe hepatic impairment (Child-Pugh class C) must be treated at
the dose of 75 mg once daily [35,45].
For ribociclib, a PK study in patients with hepatic impairments has been conducted, showing no
effect in the exposure of the drug in patients with mild impairment while in those with moderate or
severe impairment, exposure was increased less than two-fold. The results were confirmed also in
another analysis comparing 160 patients with breast cancer and normal liver function with 47 with
mild liver impairment.
Regarding abemaciclib, a PK study in patients with different degrees of liver impairment has
suggested a similar exposure of the drug in those with mild or moderate liver injury, though a lower
Cmax has also been described. In severe liver injury, exposure was 2.09 (90% CI: 1.33, 3.28) times
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higher with respect to patients with normal liver function. Similarly, half-life and Tmax were longer.
In contrast, the AUC of abemaciclib active metabolites was decreased. Globally, the increase in parental
drug exposure was outweighed by the decrease in metabolites exposure. As already described in the
PK Section 1.3, abemaciclib is highly bound to plasma protein. Its plasma protein binding decreases
with increasing severity of hepatic impairment. The average unbound fraction is 3.7% in patients with
normal liver function and increases up to 5% and 7.8% in those with moderate and severe impairment
respectively [16,46].
Although the overall reported injury of hepatotoxicity in CDKis in clinical trials has been less
than 10%, palbociclib has been associated with liver injury in some case reports [97–99]. In three of the
four reported cases, it was described a fatal liver injury.
Phase III trials with ribociclib have registered a relatively high incidence of hepatobiliary toxicity,
mainly grade 3 and 4 toxicities [7,10,11,13].
Details on dose adjustments related to hepatic impairment are reported in Table 4 and Figure 2.
Figure 2. Starting dose selection of palbociclib, ribociclib and abemaciclib, according to DDIs, DGIs or
interactions with pathophysiological conditions. No studies have been performed in hemodialyzed
patients for all the three CDKis. * In patients with severe renal impairment, treated with ribociclib,
the starting dose which is approved by EMA is 400 mg/daily vs. 200 mg/daily by FDA. # The suggested
reduced starting dose for abemaciclib is 150 mg daily. § No evidences available and no dosing
is suggested.
5.2. Renal Impairment
In a PK dedicated trial, patients with different degree of renal impairment, excluding hemodialyzed,
received palbociclib and no dose adjustment was required in any case [NCT02085538]. These data are
consistent with a population PK analysis including 73 and 29 patients with mild renal and moderate
renal impairment respectively, who did not show modified exposure to palbociclib [35,45].
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In a population treated with ribociclib, PK analysis comparing 77 patients with normal renal
function, with 76 patients with mild renal impairment and 35 with moderate renal impairment,
no differences in the exposure to the drug have been noticed among the three groups. Recently a
phase I study, aiming to evaluate ribociclib PK and safety profile in patients with varying degrees of
impaired renal function compared to healthy volunteers with normal renal function, confirmed that no
dose adjustment is necessary in patients with mild to moderate renal impairment. A starting dose of
400 mg once daily is recommended in patients with severe renal impairment [NCT02431481] [100].
Nevertheless, the FDA suggests an even further reduced dose of 200 mg once daily [10].
Abemaciclib has no dedicated PK studies in patients with renal impairment. As described in
Section 1.3, their metabolism is predominantly hepatic, and thus, according to preclinical studies and
population PK analyses, no modified excretion is expected in mild to moderate renal impairment and
no dose adjustment is needed [101].
Details on dose adjustments related to renal impairment are reported in Table 4 and Figure 2.
5.3. Gender and Hormonal Status
Researchers have shown how gender differences may contribute to variation in safety and efficacy
of drug therapy. One of the main explanations of such difference lies in PK and pharmacogenetic
differences. In fact, hormones can modify transporters and enzymes expression as well as play a
role in gastric emptying. Progesterone and estrogen can modulate gastric pH and time of transit in
stomach and bowel [102]. Woman in fact are characterized by a higher gastric pH and a lower bowel
transit [102]. As previously discussed, palbociclib absorption is highly dependent on gastric pH, also
abemaciclib absorption is influenced by food intake and this may be due to pH modifications. On this
base, we can expect a lower exposure in women with respect to men. Ribociclib absorption, instead,
is not affected by food intake [103]. Furthermore, bioavailability changes in association with gastric
pH must be considered even more because of the frequent association of oncological therapies with
gastric pH elevating drugs, such as proton pump inhibitors or H2 blocking agents.
Differences between males and females which can impact in drug exposure, have been described
also in association with transporters and drug metabolizing enzymes. At the intestine level, no
differences in P-gp expression between male and female have been described [104,105] but in liver, P-gp
expression is twice as high in females compared to male and half as much for CYP3A4 activity [106].
Some studies have also demonstrated a higher liver expression of BRCP in males with respect to
females [107]. This can be translated in a higher clearance rate of palbociclib and abemaciclib in
males, potentially offsetting metabolism differences for these drugs. Also, for drug-induced QT
prolongation, significant differences exist between male and female. In fact, women have higher
risk to incur in TdP because of QT prolongation [108]. Rodriguez et al. have also demonstrated an
association between hormonal changes during menstrual cycle and QT lengthen [109]. Thus, we expect
a higher risk of QT prolongation for women, especially those in premenopausal, that should be taken
into consideration when the CDKi of choice is ribociclib. Indeed, it has been proposed that natural
fluctuation in endogenous sex steroid hormones with the menstrual cycle, pregnancy, and menopause
could potentially influence drug efficacy and safety profile overall [110]. The physiologic decrease in
circulating estrogen in menopause has been associated with changes in drug metabolizing enzymes.
According to Paine et al. CYP3A4 activity in the intestine was 20% lower in the post-menopausal
compared to pre-menopausal women [104]. The effect of menopausal status on the PK of drugs has
been poorly investigated. The pre-menopausal status has been associated with decreased endoxifen
plasma concentrations by 135% compared to post-menopausal status in tamoxifen-treated breast cancer
patients phenotyped as NMs for CYP2D6 and with CYP3A activity [111]. The authors hypothesized
that a lower P-gp activity in the gut of post-menopausal patients could be held responsible for the
increased tamoxifen bioavailability. It may be conjectured that substrate drugs for CYP3A4 and P-gp,
as CDKis, may increase their plasmatic concentrations and toxicity in the post-menopausal status.
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Finally, it is worth reminding that CDK 4/6 inhibitors have been approved only for breast cancer
in women. Although this pathology is an almost exclusively female condition with less than 1% of all
breast cancers occur in men [112], further studies on CDKis and male breast cancers are needed in order
to provide supporting evidences for CDKis in this clinical setting. Furthermore, due to the relevant
pathophysiological involvement of sexual hormones in breast cancer, several preclinical and clinical
studies are ongoing to test CDKis in other endocrinological tumors such as ovarian cancer [113].
5.4. Inflammation and Cancer
Inflammation, caused by infectious disease or other conditions like cancer, has been associated
with the downregulation of several drug metabolizing enzymes expression [114,115] and, as previously
mentioned, can drive the phenoconversion phenomenon [25]. Cytokines such as IL1, TNF, interferons
and IL-6 are primarily involved in this mechanism [116]. Proinflammatory cytokines can suppress
biosynthesis of drug metabolizing enzymes impacting their quantities, thus affecting their capacity
of drug metabolization. This influence has been clearly demonstrated in in vitro [117–119] and
in vivo [120–122] experiments. In confirmation, Rivory et al. demonstrated that, in advanced cancer
patients, the ones with acute phase response (CRP > 10 mg/L) presented a 30% lower CYP3A metabolic
activity with respect to patients without acute phase response. This observation did not take account
of the type of oncological disease, nevertheless 9% of studied patients were suffering from breast
cancer [122]. Such phenoconversion can alter drug metabolization, exposing patients to a higher risk of
adverse events from cancer therapy. Neoplastic tissue can also contain cytochrome P450 enzymes with
the capacity to metabolize drugs. A study on breast carcinomas has revealed the overexpression in
cancer tissues of CYP3A4 and CYP2C9. Another study from 2016 hypothesized that the PXR-mediated
induction of CYP3A5 expression, common in a range of solid tumors, could increase metabolism of
taxanes and tyrosine kinase inhibitors [123]. The effects of the expression of these enzymes are still
unexplored, but they have been proposed to play a role as a resistance mechanism [124]. A better-known
mechanism of resistance consists in the increased activity or synthesis of ABC efflux transporters by the
tumor, facilitating the efflux of cancer drug and reducing intracellular drug concentrations. Elevated
levels of P-gp have been found in more than half of the NCI-60 tumor cell lines [125].
Probably, NRs activity could be modified in flogosis, since they are considered important
xenosensors mediating the impact of inflammation on the expression of ADME genes and finally on
therapy outcome [84].
With regard to phase II drug metabolizing enzymes, a reduction in sulfonation capacity has been
linked with the acute-phase inflammatory response of several infectious and inflammatory conditions.
An altered drug metabolism and the development of cholestasis have been proposed to be associated
with SULT2A1 suppression in inflammation. Sulfotransferase activity decreases significantly with the
severity of liver disease from steatosis to cirrhosis, potentially causing an increase in drug levels and
toxicity [63,126].
5.5. Brain Metastases from Breast Cancer
Brain metastases occur in 10–16% of patients with breast cancer [127]. Unfortunately, registration
studies have excluded patients with brain metastases or when they have included them, as in the
MONALEESA-3 case, specific outcomes on CNS were not discussed. In a condition of inflammation
like that caused by brain metastases, drugs penetrability through the BBB could potentially be increased.
BBB is responsible for ensuring the homeostasis of the CNS and this function is explicated by the
CNS endothelial cells which are rich of tight junctions predominately belonging to the family of
claudin (especially Cldn5 and Cldn3) and occludin. Also, pericytes, astrocytes, and microglial cells are
responsible for the impermeability of the BBB. Inflammation is linked with BBB disruption and leakage,
and this is associated with the reduced expression of claudins and occludins caused by inflammatory
mediators (IL-1β, IL-6, IL-17, IFN-γ, TNF-α). These cytokines are also able to up-regulate chemokines
and cell adhesion molecules expression thus modifying BBB permeability [128].
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Penetrability across the BBB could be further increased considering that P-gp seems to be not so
extensively expressed in the BBB of patients with metastatic brain tumor [129] and that all CDKis are
substrates of P-gp-mediated extrusion from the brain. An experimental model comparing the BBB
permeability of palbociclib and abemaciclib, more lipophilic than ribociclib, has shown that the efflux
efficiency is lower for abemaciclib than palbociclib. In vitro efflux ratios were respectively of 4.1 and
12, respectively [51]. Nonetheless, used doses are much higher than clinically relevant doses. A phase
I trial has shown that concentrations of abemaciclib can be measured in cerebrospinal fluid of patients
and radioactivity from 14C marked abemaciclib can be measured after a single oral dose of 10 mg/kg
up to 12 h [130]. An intracranial clinical benefit for 58 patients with brain metastases secondary to
HR+ metastatic breast cancer treated with abemaciclib have been demonstrated by Anders et al. at the
ASCO 2019 [131]. Specifically, 6% of patients had confirmed objective intracranial response and 38% a
decrease of intracranial lesions. Intracranial clinical benefit rate persisting for ≥6 months was 25%,
while median PFS was 4.4 months (95% CI, 2.6–5.5) [131].
A good CNS penetration has also been shown for ribociclib in mice bearing glioma cortical
allograft tumors vs. non-tumor bearing mice [52], as well as in a PK analysis of a phase 0 trial involving
recurrent glioblastoma patients, however with inconclusive results in terms of clinical efficacy [132]
that require further investigations.
In the peculiar conditions of brain metastases, palbociclib could potentially reach therapeutic
concentrations as well, regardless being a major P-gp and BCRP substrate at the BBB. Indeed, results of
an interim analysis of a phase II trial of palbociclib administration in patients with brain metastases
harboring CDK pathway alterations [NCT02896335] presented at the 24th Annual Meeting and
Education Day of the Society of NeuroOncology, revealed that 57% of the patients evaluable were
having an intracranial response after treatment with palbociclib with a median overall survival of
6.5 months (90% CI, 3.8–13.6) [133].
5.6. Obesity
Obese patients are characterized by a marked modification in drug distribution and elimination.
These patients are typically characterized by a higher first pass metabolism caused by an increase
in hepatic blood flow and hepatic clearance. Furthermore, a higher prevalence of obese patients
suffers from a condition known as NASH (non-alcoholic steato-hepatitis), characterized by fatty
infiltrations and liver inflammation. The 90% of liver biopsies of obese subjects have shown to
have these characteristics [134]. Incidence of NASH increases with Body Mass Index (BMI) and its
prevalence is estimated to be up to 20% of the obese population, rising to 50% in morbidly obese patients.
As previously discussed, inflammation can cause a decrease in drug metabolizing enzymes expression.
Moreover, renal clearance is affected by obesity, in fact these patients are associated with a state of
glomerular hyperfiltration resulting in a condition of enhanced renal clearance.
Since several studies have shown a significantly stronger association between increased BMI and
higher breast cancer incidence. This is especially true for postmenopausal women, where several
meta-analyses have consistently shown positive associations among high adiposity, adult weight gain
and risk of HR-positive breast cancer [135–137]. Moreover, a study revealed that 47.7% of patients
diagnosed with breast cancer were obese [138]. Because of the very high prevalence of obese patients
in this population, further studies to characterize PK in obese patients are needed, as recommended by
the investigation of PK and PD in the obese population published by the EMA-CHMP [139].
5.7. Age
Several modifications in drugs PK are induced also by age. Starting from drug absorption, elders
have reduced gastric acid secretion [140,141], exposing patients to a higher absorption of CDKis.
Furthermore, concurring to a higher exposure, elders are characterized by a reduction in first-pass
metabolism [142,143], probably because of a reduction in the hepatic blood flow and in tissue mass.
Significant changes in body mass composition and fat distribution, altering a lot the distribution of
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drugs in tissues have been associated with ageing process. Palbociclib and ribociclib are characterized
by a high volume of distribution and because of the age-related modifications, elders can result in
higher serum concentrations. Despite there are no evidences of alterations in the expression of serum
proteins with the age, prevalence of malnutrition among elderly is high [144] and this can have an
impact in serum albumin concentrations, which can result in a higher free fraction of CDKis. In women,
contrary to men, age induces also a reduction in the expression of P-gp [145], affecting once again
drug bioavailability. All these considerations warrant particular caution in the treatment of elderly
patients, considering that breast cancer risk increases with age and more than one third of patients
diagnosed with breast cancer are over 70 years of age [146]. Since it is a population of fragile patients at
an increased likelihood of adverse events both because their oncological disease and their age, the use
and dose of CDKis should be the most appropriate to avoid exposing them to excessive concentrations
of these drugs.
6. Mechanisms of Resistance to CDKIs
The improvements of clinical outcomes obtained with CDKis are jeopardized by the occurrence of
resistance to these treatments in some patients [147]. This phenomenon can be due to intrinsic and/or
acquires mechanisms which can be classified as cell cycle-specific and non cycle-specific [148]. Taking
in consideration the molecular pathways CDKis target, the most relevant causes of cell cycle specific
resistance are all that conditions which promote the G1–S transition of the cell cycle, such as: (i) the
loss of tumor suppressor proteins as RB and/or FZR1 [149]; (ii) amplification of proteins involved in
the CDK-complex as CDK2, CDK4, CDK6, p16, CCNE1/2, and E2F [148]; (iii) overexpression of CDK7
which support CDK4/6 activity [150]; (iv) activation of HDAC which inhibits CDK suppressors [151];
(v) alteration of other molecular check-points of cell-cycle as the overexpression of WEE1 [148]; (vi)
overexpression of proteins which inhibit cellular senescence as MDM2 [152]. On the other hand,
every other non-specific pro-oncogenic alteration not involving cell cycle specific pathways can induce
resistance, such as: (i) the activation of the FGFR and PI3K/AKT/mTOR pathways; (ii) the loss of
ER or PR expression; (iii) the higher transcriptional activity of AP-1 and/or EMT pathway; (iv) the
suppression of SMAD3 pathway; (v) the autophagy activation; (vi) immune mechanisms [148,153].
To date, several studies aim to identify patient profiles or biomarkers in order to predict the
resistance to CDKis, but no strong evidences yet emerged, and further studies are required for this
relevant unmet medical need [153,154].
7. Discussion
Current clinical questions include how to choose among palbociclib, ribociclib, and abemaciclib
and to personalize their use according to the need of each particular clinical setting in breast cancer [155].
The factors concurring in defining patient’s metabolizer phenotype and consequently the inter and
intra-patient variability associated with CDKis use are diverse. Indeed, DDIs, DGIs and patient’s
pathophysiological conditions can modify CDKis pharmacological features amplifying differences
in CDKis safety and efficacy profile. Drugs alter metabolizing enzymes, transporters, and/or efflux
pumps, inducing PK modifications that influence their efficacy or the efficacy of other co-administered
compounds. Consequently, therapeutic concentrations as well as their cytotoxic effects could therefore
undergo changes.
Germline host characteristics have been considered so far responsible for a major proportion of the
observed interindividual variability in many drugs. Subpopulation analyses in breast cancer patients
treated with CDKis highlighted differences in their safety as well efficacy profile. Different prevalence
in CYP3A4/5 and transporters (ABCB1 and ABCG2) SNPs among subpopulations have been proposed
to play a role in influencing ADME of CDKis PK. At the same time, some pathophysiological conditions
can cause a variability in PK parameters, both intra-patient as food intake, or interpatient as renal
or hepatic impairment, systemic or local inflammation status, general clinical condition, hormonal
profiles, and eventually tumor grading/staging.
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Given the pharmacological considerations about each CDKi, we can speculate that some clinical
settings could be more suitable than others for the adoption of a specific CDKi. A tailored therapeutic
approach taking into consideration all the factors potentially contributing to an altered PK/PD profile
(based on DDIs, DGIs and pathophysiological condition), could represent indeed an innovative safer
solution. It could also represent an effective strategy in the clinical decision making of CDKis use
(Figures 2 and 3).
Figure 3. Flow diagram for potential CDKi selection to increase individual safety and tolerability,
according to safety data from literature. The CDKi choice of priority is based on each patient’s clinical
feature and is arbitrary expressed by: +++, highly recommended to use; ++, moderately recommended
to use; +, lower recommended to use.
For example, abemaciclib should be avoided in patients with pre-existent gastrointestinal
comorbidities since severe nausea, vomiting and diarrhea are the most frequent adverse events
which are also able to alter abemaciclib PK profile. On the contrary, it is worth to underline that
abemaciclib has been associated with the safest toxicological profile among CDKis, due to the less
frequent neutropenia events. For patients with cardiovascular comorbidities palbociclib should be
preferred seeing the high risk of thromboembolic events [156,157] with abemaciclib and QT prolongation
risk associated with ribociclib. This is clinically relevant in breast cancer settings, considering also that
women are at higher risk of QT prolongation, since their QT interval is usually longer compared to
man [50]. In patients with mild hepatic impairment, ribociclib should be avoided since it may induce
hepatotoxicity more frequently compared with the other CDK4/6 inhibitors.
Palbociclib and ribociclib are characterized by lower binding to serum protein and thus should
be preferred in patients with advanced metastatic disease and hepatic localization, considering that
hepatic dysfunction can lead to hypoalbuminemia and consequently to a larger amount of unbound
(free) drug. Hypoalbuminemia may induce toxicity in patients treated with abemaciclib, highly bound
to serum protein. In renal impaired patients palbociclib seems to be the safest choice according to
results deriving from trials in this specific population whereas less evidences are available for the
other CDKis. Similarly, palbociclib could be preferred in patients in polytherapy (defined as more
than five co-medications) for comorbid conditions due to a lower incidence of clinically meaningful
DDIs. These suggestions should be more accurately taken in consideration in elderly patients where
hypoalbuminemia, renal impairment and polytherapy may more frequently coexist (Figure 3).
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Abemaciclib could be hypothesized to be the drug of choice in patients with brain metastases,
because of its lipophilicity along with its ability to inhibit P-gp efflux pumps and to reach therapeutic
concentration in brain tissue with lower doses compared to the other CDKis, in addition to its multiple
mechanisms of action involving CDK1 and CDK2, which are implicated in brain oncogenesis [158].
In conclusion, many pharmacological variables should be considered when choosing one treatment
or another. CDKis are not only subjected to the well-known variability related to the oral administration
route, but also to the less studied one deriving from interacting comedications, pharmacogenetic profile
and pathophysiological conditions in cancer patients. The use of a specific CDKi should shift from an
empirical approach to a more personalized one aimed both at reducing sources of variability and at
tailoring dose to the individual patient, also through the help of therapeutic drug monitoring. Dose
individualization is one of the principal challenges facing personalized medicine in such a complex
setting as cancer treatment, especially in patients affected by this big killer.
All these considerations could have also other relevant implications because CDKis have been
studying for other clinical settings. Indeed, their efficacy is under investigation in HER2-overexpressing
and triple-negative breast cancer [159], although palbociclib as a monotherapy has already shown
no efficacy in triple-negative breast cancer [160]. Furthermore, due to their complex and not deeply
understood mechanisms of action, CDKis, especially abemaciclib, have shown as monotherapy
encouraging results in preclinical models of other tumor such as glioblastoma, non-small cell lung
cancer, head and neck squamous cell carcinoma, pancreatic cancer, esophageal adenocarcinoma,
melanoma, colon cancer, myeloma, and ovarian cancer [113,161,162]. Analogously, since CDKis
influence a wide range of key functional proteins, several studies have investigated possible therapeutic
strategies combining CDKis to drugs targeting immune checkpoint such as PD-1/PD-L1 [163,164], or
other molecules interacting with the PI3K-AKT-mTOR pathway [165,166].
To conclude, CDKis are promising therapeutic agents which need to be more deeply studied in all
their clinical pharmacological properties in order to be appropriately exploited to represent the best
safety and efficacy treatment option.
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